Medicinal preparation for treating hepatobiliary diseases and preparation method thereof

A technology for pharmaceutical preparations and hepatobiliary diseases is applied in the field of pharmaceutical preparations for the treatment of hepatobiliary diseases and their preparation, and can solve the problems affecting the quality and curative effect of ursodeoxycholic acid tablets, production processes, differences in excipients and components, etc.

Active Publication Date: 2019-01-22
THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, in addition to importing ursodeoxycholic acid raw materials and preparations from abroad, there are more than 40 domestic companies producing ursodeoxycholic acid ta

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal preparation for treating hepatobiliary diseases and preparation method thereof
  • Medicinal preparation for treating hepatobiliary diseases and preparation method thereof
  • Medicinal preparation for treating hepatobiliary diseases and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Ursodeoxycholic Acid Tablets

[0033] Prescription composition (1000 tablets):

[0034]

[0035] Preparation:

[0036] ① Micronization treatment of raw materials: Micronize the raw materials of ursodeoxycholic acid to obtain more than 90% of the micropowder with a particle size of no more than 40-50 microns, and set aside;

[0037] ② Pretreatment of excipients: hydroxypropyl cellulose, starch, and magnesium stearate are respectively passed through a 120-mesh sieve, and set aside; dissolve HS-15 with 35% ethanol to prepare a binder solution, set aside;

[0038] ③ Mixing raw and auxiliary materials: mix ursodeoxycholic acid, starch, and hydroxypropyl cellulose evenly;

[0039] ④ Soft material granulation: add the powder in step ③ to the binder solution, stir to prepare soft material; take the prepared soft material and pass through a 14-mesh sieve to granulate.

[0040] ⑤ Drying and granulation: Take the prepared granules and dry them, then granulate the ...

Embodiment 2

[0042] Example 2: Ursodeoxycholic Acid Tablets

[0043] Prescription composition (1000 tablets):

[0044]

[0045] Preparation:

[0046] ① Micronization treatment of raw material drug: micronized ursodeoxycholic acid raw material drug to obtain more than 90% of the micropowder with a particle size of no more than 40-50 microns, and set aside;

[0047] ②Excipient material pretreatment: hydroxypropyl cellulose, starch, and magnesium stearate are respectively passed through a 100-mesh sieve, and set aside; dissolve HS-15 with 40% ethanol to prepare a binder solution, set aside;

[0048] ③ Mixing raw and auxiliary materials: mix ursodeoxycholic acid, starch, and hydroxypropyl cellulose evenly;

[0049] ④ Soft material granulation: add the powder in step ③ to the binder solution, stir to prepare soft material; take the prepared soft material and pass through a 14-mesh sieve to granulate.

[0050] ⑤ Drying and granulation: Take the prepared granules and dry them, then granulat...

Embodiment 3

[0052] Example 3: Ursodeoxycholic Acid Tablets

[0053] Prescription composition (1000 tablets):

[0054] components

Weight (g)

number of copies

ursodeoxycholic acid

50

10

low substituted hydroxypropyl cellulose

12.5

2.5

starch

9

1.8

Magnesium stearate

2.5

0.5

HS-15

1

0.2

38% ethanol solution

53

—

[0055] Preparation:

[0056] ① Micronization treatment of raw material drug: micronized ursodeoxycholic acid raw material drug to obtain more than 90% of the micropowder with a particle size of no more than 40-50 microns, and set aside;

[0057]②Excipient material pretreatment: hydroxypropyl cellulose, starch, and magnesium stearate are respectively passed through a 100-mesh sieve, and set aside; dissolve HS-15 with 38% ethanol to prepare a binder solution, set aside;

[0058] ③ Mixing raw and auxiliary materials: mix ursodeoxycholic acid, starch, and hydroxypropyl cellulose evenly...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides a medicinal preparation for treating hepatobiliary diseases and a preparation method thereof. The medicinal preparation comprises ascariasis, hydroxypropyl cellulose, starch, magnesium stearate, HS-15 and an ethanol solution for preparing a soft material. The dissolution curves of an ascariasis tablet provided by the invention in four mediums are consistent with those of anoriginal product, thereby ensuring the same efficacy as the original product.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, more specifically, to a pharmaceutical preparation for treating hepatobiliary diseases and a preparation method thereof. Background technique [0002] The chemical composition of bear bile is relatively complex, including bile acids, cholesterol, bile pigments, amino acids, and trace elements. Bile acids include cholic acid (CA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), deoxycholic acid (DCA), tauroursodeoxycholic acid (TUDCA), taurine Chenodeoxycholic acid (TCDCA) and so on. Ursodeoxycholic acid (UDCA for short) is the main component of bear bile, its chemical name is 3α, 7β-dihydroxy-5β-cholanic acid, which is the 7β-hydroxyl Epimers. [0003] [0004] Since the discovery that UDCA could effectively dissolve cholesterol gallstones in the 1980s, new studies have shown that UDCA has positive effects in the treatment of hepatobiliary diseases, especially in the tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K47/38A61K47/36A61K47/34A61K31/575A61P1/16
CPCA61K9/2031A61K9/2054A61K9/2059A61K9/2095A61K31/575A61P1/16
Inventor 赵晓娟王永静赵永红律涛
Owner THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap